PURPOSE: Bioavailability of clopidogrel in the form of crushed tablets administered via nasogastric tube (NGT) has not been established in patients after cardiopulmonary resuscitation. Therefore, we performed a study comparing pharmacokinetic and pharmacodynamic response to high loading dose of clopidogrel in critically ill patients after cardiopulmonary resuscitation (CPR) with patients scheduled for elective coronary angiography with stent implantation. METHODS: In the NGT group (nine patients, after cardiopulmonary resuscitation, mechanically ventilated, therapeutic hypothermia), clopidogrel was administered in the form of crushed tablets via NGT. Ten patients undergoing elective coronary artery stenting took clopidogrel per os (po) in the form of intact tablets. Pharmacokinetics of clopidogrel was measured with high-performance liquid chromatography (HPLC) before and at 0.5, 1, 6, 12, 24 h after administration of a loading dose of 600 mg. In five patients in each group, antiplatelet effect was measured with thrombelastography (TEG; Platelet Mapping) before and 24 h after administration. RESULTS: The carboxylic acid metabolite of clopidogrel was detected in all patients in the po group. In eight patients, the maximum concentration was measured in the range of 0.5-1 h after the initial dose. In four patients in the of NGT group, the carboxylic acid metabolite of clopidogrel was undetectable and in the remaining patients was significantly delayed (peak values at 12 h). All patients in the po group reached clinically relevant (>50 %) inhibition of thrombocyte adenosine diphosphate (ADP) receptor after 24 h compared with only two in the NGT group (p = 0.012). There was a close correlation between peak of inactive clopidogrel metabolite plasmatic concentration and inhibition of the ADP receptor (r = 0.79; p < 0.001). CONCLUSION: The bioavailability of clopidogrel in critically ill patients after cardiopulmonary resuscitation is significantly impaired compared with stable patients. Therefore, other drugs, preferentially administered intravenously, should be considered.

Department of Anaesthesiology and Intensive Care University Hospital St Anne's Brno Brno Czech Republic

Zobrazit více v PubMed

Circulation. 2006 Nov 28;114(22):e600-6 PubMed

Am Heart J. 2008 Dec;156(6):1080-1088.e1 PubMed

Thromb Res. 2007;120(3):353-9 PubMed

Br J Anaesth. 2009 Apr;102(4):492-8 PubMed

Crit Care Med. 2009 Jul;37(7 Suppl):S186-202 PubMed

Thromb Res. 2007;120(3):311-21 PubMed

Circulation. 2008 Jan 15;117(2):296-329 PubMed

Circulation. 2001 May 29;103(21):2572-8 PubMed

J Am Coll Cardiol. 2007 Feb 13;49(6):657-66 PubMed

Platelets. 2006 Dec;17(8):509-18 PubMed

J Am Coll Cardiol. 2005 May 3;45(9):1392-6 PubMed

J Am Coll Cardiol. 2007 Apr 10;49(14):1505-16 PubMed

Heart. 2001 Jan;85(1):92-3 PubMed

N Engl J Med. 2001 Aug 16;345(7):494-502 PubMed

N Engl J Med. 2009 Jan 22;360(4):363-75 PubMed

Eur J Cardiothorac Surg. 2010 Jun;37(6):1367-74 PubMed

Circulation. 2000 Jun 13;101(23):2690-5 PubMed

World J Gastrointest Endosc. 2010 May 16;2(5):155-64 PubMed

Circulation. 2003 Jun 17;107(23):2908-13 PubMed

JAMA. 2005 Sep 14;294(10):1224-32 PubMed

Nephrol Dial Transplant. 2004 Mar;19(3):623-30 PubMed

Semin Thromb Hemost. 1999;25 Suppl 2:25-8 PubMed

Lancet. 1996 Nov 16;348(9038):1329-39 PubMed

N Engl J Med. 2009 Jan 22;360(4):354-62 PubMed

Eur Heart J. 2005 Apr;26(8):804-47 PubMed

Thromb Res. 2011 Jun;127(6):518-24 PubMed

Am J Cardiol. 2009 Feb 2;103(3 Suppl):20A-26A PubMed

Scand J Clin Lab Invest. 2011 Dec;71(8):637-40 PubMed

Circulation. 2002 Oct 22;106(17):2284-7 PubMed

Circulation. 2004 Nov 9;110(19):e489-93 PubMed

Eur Heart J. 2011 Dec;32(23):2999-3054 PubMed

J Interv Cardiol. 2009 Aug;22(4):385-9 PubMed

Thromb Haemost. 2004 Aug;92(2):311-6 PubMed

Arterioscler Thromb. 1992 Apr;12(4):430-6 PubMed

Crit Care Med. 2007 Sep;35(9):2196-204 PubMed

Br J Anaesth. 1997 Jan;78(1):34-8 PubMed

Am J Cardiol. 2006 Sep 1;98(5):681-4 PubMed

Circulation. 2010 Apr 20;121(15):1713-21 PubMed

Curr Opin Crit Care. 2007 Apr;13(2):187-94 PubMed

Cardiovasc Ther. 2011 Dec;29(6):e100-11 PubMed

Eur Heart J. 2004 Mar;25(6):454-6 PubMed

J Thromb Haemost. 2007 Dec;5(12):2429-36 PubMed

Rapid Commun Mass Spectrom. 2006;20(11):1695-700 PubMed

Drug Metab Dispos. 2002 Nov;30(11):1288-95 PubMed

Blood Coagul Fibrinolysis. 2012 Jun;23(4):285-9 PubMed

J Am Coll Cardiol. 2005 Apr 19;45(8):1157-64 PubMed

J Surg Res. 2010 Jan;158(1):121-6 PubMed

Blood Coagul Fibrinolysis. 2010 Dec;21(8):770-4 PubMed

Anesth Analg. 2001 Jan;92(1):5-11 PubMed

J Lab Clin Med. 2004 May;143(5):301-9 PubMed

Thromb Res. 2008;122(6):776-81 PubMed

Circulation. 2005 Nov 8;112(19):2946-50 PubMed

Antiplatelet efficacy of P2Y12 inhibitors (prasugrel, ticagrelor, clopidogrel) in patients treated with mild therapeutic hypothermia after cardiac arrest due to acute myocardial infarction

Routine pretreatment with abciximab versus standard periprocedural therapy in mechanically ventilated cardiogenic shock patients undergoing primary percutaneous coronary intervention: Subanalysis of the PRAGUE-7 study